Back to search results

Pharmacogenomic Analysis for Pain Treatment in Cancer Patients

This study is looking at how using Pharmacogenomic (PGx) results, which are genetic test results that help doctors choose the right medicine and dose for you, can improve pain control in adult cancer patients. The study will compare patients who receive this genetic testing to those who don't, to see if it helps with opioid (pain medication) dosing and pain scores. You might be able to join if you are at least 18 years old, are receiving cancer care at the University of Chicago Medical Center, and are expected to need opioid pain medication soon. You cannot join if you are currently taking opioids or have taken them in the last 30 days, or if you are having palliative radiation. The main goal is to see how well pain is controlled after 45 days. The current recruitment status is unclear.

Study design
This is a randomized study, meaning participants are assigned by chance to different groups, with a planned enrollment of 800 people.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Pain control will be measured at 45 days after starting the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06511401

Informing Pain Treatment Using Pharmacogenomic Analysis

Recruiting
NAAges 18+InterventionalSupportive care
University of Chicago
~800 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Pharmacogenomic (PGx) results.

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Pain control.
Measured over 45 days

Conditions

Adult Patients Who Are Receiving Oncologic Care

Explore related trials

Malignant Neoplasm

Where it's being run

1 sites across 1 states
Illinois1

Study leadership

  • Peter H O'Donnell · PRINCIPAL_INVESTIGATOR · University of Chicago

Who to contact

Clinical Trials Intake
[email protected]
1-855-702-8222
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Persons receiving ongoing oncology care at the University of Chicago Medical Center for whom near-future pain opioid pain medication therapy is anticipated
Subjects must be at least 18 years of age.

Exclusion

Subjects taking an opioid at the time of enrollment, or within the past 30 days
Subjects who are currently undergoing palliative radiation
Subjects who have undergone, or are being actively considered for, bone marrow, liver or kidney transplantation.
Subjects with a history of or active blood cancer (e.g., leukemia).
Chronic kidney disease, as defined by Glomerular filtration rate (GFR) \< 30/mL/min/1.73m2, due to the risk of decreased drug excretion.
Liver dysfunction, as defined by the following laboratory values, due to the risk of decreased drug metabolism: Total bilirubin greater than or equal to1.5 mg/dL, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) greater than or equal to 2.5 X upper limit of normal\*. (\*Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \\ greater than or equal to 5 X upper limit of normal if hepatic metastases are present).
Inability to understand and give informed consent to participate in the opinion of the investigator
Subjects who are known to be pregnant at the time of enrollment
Subjects who have previously or are currently enrolled in another institutional pharmacogenomic genotyping study, or are known to have previously undergone pharmacogenomic genotyping for the gene(s) of interest via another commercial or other means.

What this trial measures

  • Pain control.45 days

    Measuring changes in composite pain intensity rating via the numeric rating scale: * Brief Pain Inventory-Short Form (BPI-SF) * Score range: 0 (no pain) to 10 (most pain) * Composite pain intensity score (mean of worst, least, average, and current pain) From baseline to day 45 in patients receiving an index opioid prescription for codeine, tramadol, or hydrocodone.